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Abstract
Background: Inflammation and skeletal muscle wasting often coexist in elderly populations, but few studies have
examined their relationship in elderly heart failure (HF) patients. This study examined the relationship between
inflammation and increased skeletal muscle proteolysis, reduced skeletal mass and strength, and their prognostic
implications in elderly HF patients (> 65 years) using a random forest approach.
Methods: We prospectively enrolled consecutive elderly HF patients (n = 78) and age- and sex-matched control
subjects (n = 83). We measured the interleukin (IL)-6, C-reactive protein (CRP), and B-type natriuretic peptide (BNP)
levels, lower limb muscle mass and strength, and 6-min walk distance. The amount of muscle proteolysis was
determined by urinary 3-methylhystidine, normalized by creatinine (3-MH/Cr). The composite endpoint was defined
as all-cause death or hospitalizations due to worsening HF.
Results: Compared to controls, elderly HF patients had a significantly higher IL-6, CRP, BNP, and 3-MH/Cr, and
exhibited a reduced lower limb muscle mass and strength. A correlation analysis demonstrated significant positive
correlations between the inflammatory cytokine levels and 3-MH/Cr and BNP, and negative correlations with the
lower limb muscle mass and strength, and 6-min walk distance. During a median follow-up of 2.4-years, 24 patients
reached the endpoint. A random forest model revealed that inflammatory cytokines, skeletal muscle wasting, and
the BNP had greater effects on the risk prediction. The algorithm achieved an area under the receiver operating
characteristic curve of 0.887 (95% CI, 0.772–1.000).
Conclusion: This study provided evidence of the association between inflammation and increased skeletal muscle
proteolysis, reduced skeletal mass and strength, and their prognostic roles in elderly HF patients.
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Background
Age-related loss of the skeletal muscle mass and func-
tion, so called sarcopenia, can lead to physical disability
and an increased risk of death [1, 2]. Although the eti-
ology of sarcopenia remains multifaceted, age-related
chronic inflammation has been implicated in muscle
wasting and related sequelae. In early studies, higher
levels of interleukin (IL)-6 and C-reactive protein (CRP)
have been shown to be associated with a greater loss of
muscle mass and strength in a community-dwelling
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elderly population [3, 4]. Recent evidence suggests that
the signaling pathways related to inflammation may be
associated with anabolic deficiencies and/or excessive
muscle proteolysis [5].
Heart failure (HF) has become a significant global epi-
demic for patient populations of all ages; however, in the
elderly, there may be differences in the co-morbidities
and outcomes compared to younger HF patients [2, 6–
8]. One co-morbidity that has received increasing atten-
tion in elderly HF is sarcopenia. Examination of muscle
biopsies obtained from patients with HF demonstrated
fiber atrophy and increased numbers of inflammatory
cells [8]. These findings were associated with elevated
levels of the inflammatory cytokines, suggesting a poten-
tially shared pathogenesis of skeletal muscle atrophy in
elderly HF and aged people and implicate systemic and/
or local inflammation as a potential causative mechan-
ism of skeletal muscle wasting.
Examination of the association between inflammatory
cytokines and muscle proteolysis that promote muscle
loss is important because it may yield targets for thera-
peutic intervention. Thus, the aim of this study was to
examine whether increased inflammatory cytokines were
correlated with excessive proteolysis and a greater loss
of skeletal muscle mass, strength, and function in elderly
HF patients. Furthermore, we investigated the prognostic
role of the inflammatory cytokine levels and skeletal
muscle wasting using a random forest approach, one of




We prospectively enrolled consecutive elderly HF pa-
tients and age- and sex-matched control subjects in the
cardiology department between January 2014 and June
2016. The eligibility requirements of HF at the time of
screening included an age > 65 years, a B-type natriuretic
peptide (BNP) level > 100 pg/mL and received an opti-
mal stable pharmacological therapy [10]. In addition,
they had a history of hospitalization due to HF but had
no hospitalization due to HF in the 3 months prior to
enrollment. The HF patients presented with symptoms
(e.g. breathlessness, ankle swelling and fatigue) that were
accompanied by signs (e.g. elevated jugular venous pres-
sure, pulmonary crackles and peripheral edema) of wors-
ening HF upon hospitalization, which improved with
pharmacological treatment and/or mechanical circula-
tory support [11]. We did not consider the left ventricu-
lar ejection fraction (LVEF) as a criterion for enrollment.
We excluded those patients who had acute infectious
diseases, connective tissue diseases, chronic kidney dis-
ease (estimated glomerular filtration rate < 30 mL/min/
1.73 m2), heart transplantations, had a systolic blood
pressure > 180 mmHg, and/or a diastolic blood pres-
sure > 100 mmHg. We also excluded any patients who
had experienced myocardial infarctions, angina pectoris,
or strokes/transient ischemic attacks within the last 6
months, lower limb disabilities, or orthopedic pain or
neurologic symptoms.
Assessment of skeletal muscle proteolysis
We measured urinary 3-methylhistidine (3-MH) to as-
sess skeletal muscle proteolysis. The amino acid, 3-MH,
is generated by post-translational methylation of histi-
dine residues derived from actin and myosin degrad-
ation [12]. It cannot be further catabolized, or recycled
for protein synthesis, and is excreted in the urine.
Therefore, it reflects the myofibril protein turnover
[13]. All patients collected 24-h urine into bottles con-
taining hydrochloric acid. The 3-MH in the urine was
measured by a precolumn derivatization using reagent
3-aminopyridyl-N-hydroxysuccinimidyl carbamate
(APDSTAG WAKO, FUJIFILM WAKO Inc. Osaka,
Japan), followed by reversed-phase high-performance li-
quid chromatography and electrospray ionization tan-
dem mass spectrometry (LCMS-2020, Shimadzu
Corporation, Kyoto, Japan). The urine creatinine was
analyzed by a Jaffe reaction. The amount of skeletal
muscle proteolysis was determined as the ratio of the
urinary 3-MH to creatinine (3-MH/Cr) because 3-MH
is influenced by the renal function. All patients were
asked to refrain from ingesting soy-based products and
meat 3 days before the measurement because of a pos-
sible effect on the 3-MH.
Assessment of lower limb muscle mass and strength
The lower limb skeletal muscle mass was assessed by the
thigh circumference and thigh muscle thickness (thick-
ness of the rectus femoris and vastus intermedius) of the
dominant lower limb. The thigh circumference was mea-
sured 10 cm above the knee. The thigh muscle thickness
was measured at the midpoint of the line connecting the
upper border of the knee and anterior superior iliac
spine using B-mode ultrasonography at 3-MHz, with a
4.6 cm linear transducer array (iE33, Philips, Amsterdam,
The Netherlands) by a single sonographer unaware of
clinical information [14]. The lower limb skeletal muscle
strength was assessed by an isometric maximum volun-
tary contraction of knee extensor in the dominant leg
using a portable dynamometer (μTas F-100, ANIMA,
Tokyo, Japan) [15]. All subjects were studied while
seated in a straight-backed chair. The pelvis was secured
with a belt to prevent hip joint extension. The lower leg
was kept dependent and the knee flexed to 90° with its
posterior aspect positioned at the front edge of the chair.
The force was measured with a strap looped around the
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dominant leg just above the ankle. The knee extensor
strength was measured 3 times, and the greatest strength
was used for the analysis. The knee extensor strength
was expressed in kg.
Six-minute walk test
A 6-min walk distance test was conducted to assess the
physical performance. In this test, the patients com-
pleted as many laps of a 30 m walkway as they could in
a 6 min period, supervised by a laboratory technician.
Blood samples and echocardiography
Blood tests and two-dimensional echocardiography
were performed upon study enrolment. To avoid the
effect of exercise testing on the IL-6, blood sampling
was performed following echocardiography in the su-
pine position. Blood samples were collected from a per-
ipheral vein into tubes containing aprotinin and
ethylene diamine tetra acetic acid. The blood samples
were centrifuged at 1000×g at 4 °C for 15 min to isolate
serum or plasma and store it at − 80 °C until assayed.
The plasma BNP concentration was measured using a
chemiluminescence enzyme immunoassay for human
BNP (LLMIPULSE Presto, Fujirebio Inc. Tokyo, Japan).
The serum IL-6 concentration was measured using a
chemiluminescence enzyme immunoassay for human
IL-6 (human IL-6 measurement kit, Fujirebio Inc.
Tokyo Japan) and serum high-sensitivity C-reactive
protein (CRP) levels via a latex-enhanced hs-CRP im-
munoassay (N-Latex CRP II, Siemens Healthineers,
Tokyo, Japan). A single echocardiographer who was
blinded to the patients’ clinical information performed
offline echocardiographic analysis using a Vivid 7 (GE
Healthcare, Boston, Massachusetts, USA).
End point and follow-up
The end point was defined as either all-cause death or
hospitalizations due to worsening HF. The follow-up
data of the patients were determined from their medical
records. The data of those who did not revisit our hos-
pital were obtained by a telephone interview of the pa-
tient, patient’s family, or family doctor. The study
protocol was approved by the ethics committee of the
Fujita Health University School of Medicine, approval
number 14–031. Each participant provided written in-
formed consent. The investigation was performed in ac-
cordance with the ethical standards as laid down in the
1964 Declaration of Helsinki and its later amendments.
Statistical analysis
Continuous variables are presented as either the mean ±
standard deviation (SD) value or median [interquartile
range, IQR], and categorical variables as the frequency
and percentage. Continuous variables were compared
with Student’s t-test and χ2 test was used for categorical
data comparisons. The relationship between the clinical
variables was assessed by a Spearman’s rank correlation
analysis. We used a random forest approach for survival
analysis [9]. A random forest consists of many individual
decision trees, where a decision tree is a flowchart-like
diagram that shows a series of judgment conditions (if-
then rules). Each individual tree in the random forest
provides a class prediction (e.g., categorized as having a
high or low mortality risk) independently, and the class
with the most votes becomes the final prediction. The
fundamental idea behind the random forest is the wis-
dom of crowds. While some tree decisions in the forest
may be wrong, many other decisions would be right.
Therefore, as a group, the forest’s decision can move in
the correct direction. The random forest, like a logistic
model classifier, provides a probability estimate (ranging
from 0 to 1) for each patient to belong in the high mor-
tality class. Using the value of the estimated probability,
we drew the receiver operating characteristic (ROC)
curve. An optimal cutoff value (cutoff probability) was
defined as the point closest to the point (0, 1) on the
ROC curve. We considered 29 variables for this analysis
(Supplementary file 1). To evaluate the importance of
each covariate, the mean decrease impurity (Gini im-
portance) was measured on a training dataset. Only co-
variates of the mean decrease impurity > 0 were used for
testing. The performance of the model was assessed by
the leave-one-out cross-validation. Each random forest
model was comprised of 1000 trees, which provided a
robust classification in determining the prognosis for
each individual patient. We also performed a multiple
logistic regression analyses using backward elimination
procedure. The time-to-event curve describing the pro-
portion of patients remaining endpoint-free was calcu-
lated by the Kaplan-Meier method and compared with
the log-rank test. A two-tailed p-value of < 0.05 was con-
sidered significant. Statistical analyses were performed
using JMP 10.0.2 software (SAS Institute, Cary, NC,
USA), the Scikit-learn machine learning library in Py-
thon and R-project for Statistical Computing 3.2.2
software.
Results
Clinical characteristics of the patients
The patient characteristics are listed in Table 1. The
average age of the total 161 patients was 72 ± 7 years and
32% were female. Compared with the controls (n = 83),
the HF patients (n = 78) had a higher CRP, IL-6 and
BNP. Also, HF patients exhibited a lower hemoglobin,
reduced LVEF compared to the controls. In the control
subjects, 10 patients had an LVEF< 50%.
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Lower limb skeletal muscle measurements and the 6-min
walk test
The results of the skeletal muscle measurements and 6-
min walk test are summarized in Table 2. The HF pa-
tients had a smaller thigh circumference, reduced thigh
muscle thickness, and a weaker knee extensor strength
compared to the controls. The 3-MH/Cr in the HF
patients was greater than that in the controls. The 6-min
walk distance was significantly shorter in the HF
patients.
Spearman’s rank correlation analyses
The relationships between the clinical features and skel-
etal muscle measurements in the control and HF pa-
tients are shown in the Tables 3 and 4. The IL-6 or CRP
did not have significant correlations with thigh circum-
ference, rectus femoris thickness, and 3-MH/Cr in the
control subjects. In the HF patients, however, there were
significant positive correlations between the inflamma-
tory cytokines (IL-6 and CRP) and 3-MH/Cr and BNP,
and negative correlations with the rectus femoris thick-
ness, knee extensor strength, and 6-min walk distance.
Random forest and survival analyses
During the median follow-up period of 2.4 years [1.0–
3.6 years], 24 patients reached the endpoint. In the con-
trol subjects, no patients died but 2 hospitalized due to
HF. In the HF patients, 15 died of HF (n = 7) or sudden/
unwitnessed death (n = 8), and 7 hospitalized due to HF.
Figure 1 shows the results of mean decrease impurity of
the leave-one-out cross-validation. The BNP followed by
LVEF, inflammatory cytokines, and knee extensor
strength were the highest ranked feature for a risk pre-
diction. Four of the top 10 ranked features were skeletal
muscle-related parameters (knee extensor strength, 6-
min walk distance, rectus femoris thickness and 3-MH/
Cr). A female sex did not contribute to the risk predic-
tion. Using a ROC curve (Fig. 2a), we calculated the op-
timal cut-off value to identify the patients in the high-
risk group and low-risk group. This had a sensitivity of
83.7% and specificity of 85.7%. The area under the ROC
curve was 0.887 (95% confidence interval 0.772–1.000).
The Kaplan-Meier plots are shown in Fig. 2b. A multiple
logistic regression analyses revealed that the area under
the ROC curve was 0.674 (95% confidence interval
0.514–0.835), which was significantly lower (p < 0.01)
than that in the random forest approach (Supplementary
File 2). It showed that the BNP, age and systolic blood
pressure were independent predictors.






Age (years) 72 ± 5 73 ± 8 0.21
Female 24 (29) 28 (36) 0.15
Body mass index (kg/m2) 23.3 ± 3.5 22.8 ± 4.2 0.42
Systolic blood pressure (mmHg) 123 ± 17 125 ± 23 0.69
Diastolic blood pressure (mmHg) 75 ± 13 76 ± 14 0.51
Cardiac rhythm 0.40
Sinus rhythm 35 (42) 23 (29)
Paroxysmal/persistent AF 48 (58) 55 (71)
Medical comorbidities
Coronary artery disease 6 (7) 6 (8) 0.86
Valvular disease 1 (1) 10 (13) < 0.001
Hypertension 30 (36) 38 (49) 0.11
Diabetes 10 (12) 16 (21) 0.14
Dyslipidemia 17 (20) 14 (18) 0.68
TIA/Stroke 4 (5) 11 (14) < 0.05
Laboratory data
Hemoglobin (g/dL) 13.8 ± 11.7 12.7 ± 2.0 < 0.001
Creatinine (mg/dL) 0.83 ± 0.19 0.88 ± 0.39 0.36
eGFR (mL/min/1.73m2) 68 ± 17 66 ± 18 0.39
CRP (mg/dL) 0.16 ± 0.26 0.70 ± 1.16 < 0.001
IL-6 (pg/mL) 3.30 ± 3.71 8.08 ± 7.05 < 0.001
Creatine kinase (IU/L) 91 ± 33 92 ± 50 0.87
BNP (pg/mL) 41 ± 28 328 ± 249 < 0.001
LVEF (%) 56 ± 11 45 ± 16 < 0.001
LAD (mm) 35 ± 5.8 40 ± 7.4 < 0.001
Medications
β-Blocker 59 (71) 75 (96) < 0.001
ACE-I/ARB 29 (35) 66 (85) < 0.001
Loop diuretics 4 (5) 31 (40) < 0.001
Aldosterone blocker 5 (6) 18 (23) < 0.01
Calcium blocker 23 (28) 19 (24) 0.56
Statin 16 (19) 27 (35) < 0.05
Aspirin 10 (12) 21 (27) 0.16
Anticoagulant 48 (58) 56 (72) 0.09
AF Atrial fibrillation, TIA Transient ischemic attack, eGFR Estimated glomerular
filtration rate, CRP High-sensitivity C-reactive protein, IL-6 Interleukin 6, BNP B-
type natriuretic peptide, LVEF Left ventricular ejection fraction, LAD Left atrial
dimension, ACE-I Angiotensin converting enzyme inhibitor, ARB Angiotensin II
type 1 receptor blocker. Data represent the number, frequency, or means±SD







Thigh circumference (cm) 48 ± 7.2 42 ± 8.2 < 0.001
Thigh muscle thickness (cm) 2.9 ± 0.2 1.8 ± 0.3 < 0.001
Knee extensor strength (kg) 19.7 ± 6.4 13.9 ± 4.4 < 0.001
3-MH/Cr (nmol/g Cr) 191 ± 144 386 ± 445 < 0.001
6-min walk distance (m) 570 ± 45 534 ± 45 < 0.001
3-MH 3-methylhystidine, Cr Creatinine. Data represent means±SD
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Discussion
In this study we investigated the associations between
the inflammatory cytokines and skeletal muscle prote-
olysis, muscle mass, and strength in elderly HF pa-
tients. Furthermore, we examined their prognostic
role using a random forest approach. We found that
[1] elderly HF patients had excessive muscle proteoly-
sis, and reduced skeletal muscle mass and strength
compared to controls, [2] inflammatory cytokines and
BNP were positively associated with increased muscle
proteolysis and negatively associated with muscle
mass and strength, and [3] the random forest ap-
proach could be effectively applied to predict
outcome.
Skeletal muscle is a major reservoir of proteins in
the body and is involved in its endocrine and meta-
bolic activity as well as immune function [1, 2, 6]. A
reduced skeletal muscle mass and strength are signifi-
cant co-morbidities in elderly HF patients and lead to
weakness, loss of independence, and an increased risk
of death [1, 7]. A previous study has shown a higher
prevalence of muscle wasting in elderly HF patients
Table 3 Relationships between the clinical features and skeletal muscle measurements in the controls









AF −0.14 − 0.04
CRP −0.06 − 0.16 − 0.12
IL-6 0.08 −0.13 − 0.18 0.53§
BNP 0.02 0.21 0.13 0.07 0.17
LAD −0.05 − 0.10 0.16 0.26* 0.27* 0.43§
LVEF −0.03 0.05 0.01 −0.22* − 0.26* − 0.15 − 0.19
Thigh circumference −0.29* − 0.40# − 0.15 −0.15 − 0.03 − 0.40# − 0.17 −0.02
Rectus femoris
thickness
−0.32* −0.40# − 0.11 −0.12 − 0.10 −0.16 − 0.02 0.09 0.58§
Knee extensor
strength
−0.37# −0.32# − 0.10 −0.10 − 0.15 −0.31 − 0.04 0.16 0.43# 0.64 §
3-MH/Cr 0.22* 0.16 −0.17 0.09 0.13 0.17 0.03 −0.16 0.05 −0.14 −0.23*
6-min walk distance −0.29* −0.14 − 0.07 −0.30# − 0.57§ −0.41# − 0.43§ 0.18 0.34# 0.29* 0.25* −0.22*
The abbreviations are as in Tables 1 and 2. *P < 0.05, #p < 0.01, §p < 0.001
Table 4 Relationships between the clinical features and skeletal muscle measurements in the heart failure patients










CRP 0.13 0.10 0.11
IL-6 0.22 0.07 0.21 0.51§
BNP 0.31# 0.04 0.31# 0.31# 0.50§
LAD 0.05 −0.07 0.22* 0.16 0.05 0.24*
LVEF 0.08 −0.08 − 0.23 −0.32§ − 0.52§ −0.49§ − 0.20
Thigh
circumference
−0.41# −0.14 0.13 −0.17 − 0.22 −0.40# − 0.02 0.32#
Rectus femoris
thickness
−0.35# −0.31* 0.07 −0.27# − 0.41§ −0.42§ − 0.05 0.31# 0.49§
Knee extensor
strength
−0.36# −0.21 0.05 −0.36# − 0.41§ −0.60§ − 0.14 0.43§ 0.50§ 0.69§
3-MH/Cr 0.09 0.17 0.26* 0.21# 0.28# 0.26# 0.14 −0.12 −0.26* −0.24* − 0.22*
6-min walk
distance
−0.19 −0.14 0.10 −0.42§ − 0.77§ −0.42§ − 0.16 0.46§ 0.23* 0.32* 0.37# −0.28*
The abbreviations are as in Tables 1 and 2. *P < 0.05, # p < 0.01, § p < 0.001
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Fig. 1 The mean decreased impurity from cross-validation procedure. This figure is sorted by the order of contribution of each variable for risk
prediction. The random forest model selected 19 variables
Fig. 2 a Receiver operating characteristics curve. The cutoff points for the dichotomization (0.499) were determined by maximizing the sensitivity
and specificity of the receiver-operating characteristics curve. b Kaplan-Meier survival analysis. The Kaplan-Meier analysis demonstrated a
significantly higher event rate in patients classified as a high-risk group by a random forest model (hazard ratio 22.3, log-rank test, p < 0.0001)
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compared with healthy subjects of the same age [16].
The finding of this research is consistent with our
study, where elderly HF patients had lower muscle
mass and strength compared to age- and sex-matched
controls. We further found that elderly HF patients
had a greater loss of skeletal muscle evidenced by an
increased excretion of urinary 3-MH/Cr despite rela-
tively preserved 6-min walk distance. This observation
suggests that even small imbalances of muscle synthe-
sis and proteolysis could eventually lead to reduced
skeletal muscle mass and strength.
The contractile proteins of skeletal muscle including
actin and myosin, are methylated following peptide
bond synthesis, with production of 3-MH. The meas-
urement of the 3-MH excretion has been shown to
provide a reliable measure of muscle protein turnover
because the 3-MH is not reused for protein synthesis
and has an excretion half-life of 12.2 h [12, 13, 17–
22]. Studies on the quantitative excretion following
(14C) 3-MH administration in humans have shown
that no (14C) 3-MH is expired in the breath, while
99% of (14C) 3-MH is detected in the urine in 48 h.
Furthermore, the urinary radioactivity rose progres-
sively from 40% in rats weighing 50 g to 90% in ani-
mals weighing over 250 g [17]. This result suggested
that proteolysis increased in proportion to the in-
crease in the muscle mass. In the clinical setting, pre-
vious studies examined the turnover rate of muscle
proteins using 3-MH/Cr under various nutritional
conditions including high and low dietary protein
levels [23], starvation [24], and glucocorticoid admin-
istration [25]. Furthermore, an increased urinary ex-
cretion of 3-MH in the catabolic state such as severe
injury, thyrotoxicosis, cancer, and open-heart surgery
were reported [13, 15, 26]. In this study, all patients
had a normal diet and did not take glucocorticoids,
but we could not control the potential confounders
such as usual dietary protein level because we did not
assess the daily dietary intake or dietary supplements.
Also, a dietary protein restriction for this study might
have affected the 3-MH/Cr.
In this study the CRP and IL-6 levels positively cor-
relate with muscle proteolysis in the HF patients but
not in controls. Our result is supported by a previous
study which showed that IL-6 was as an independent
predictor of an accumulated postoperative 3MH/Cr
level in patients underwent open heart surgery [15].
Much evidence suggests that the pathogenesis of skel-
etal muscle loss in HF includes neurohormonal acti-
vation and inflammation [3, 4, 8]. A previous
experimental study showed that the sympathetic nerve
activation and increased catecholamine level in a
mouse model of HF resulted in sarcomere loss,
myocyte death, and capillary rarefaction [27].
Inflammatory cytokine signaling has been reported to
exert skeletal myocyte injury, atrophy, and generation
of reactive oxygen intermediates. Zhang et al. showed
that rodents with a constant infusion of angiotensin
II, which caused muscle loss with increasing IL-6
leads to insulin/insulin-like growth factor 1 (IGF-1)
signaling suppression [28]. Dalla Libera et al. showed
that treatment of IGF-1 improved the muscle atrophy
and exercise capacity in a mouse model of HF [29].
Persistent elevations of inflammatory cytokines in sar-
copenia patients were associated with impaired satel-
lite cell regeneration [30] as well as reductions in
endothelial reactivity and muscle perfusion, which are
essential for muscle energetics and protein anabolism
[31]. Finally, a recent report showed that CRP can
contribute to an age-related decline in the muscle
function by inhibiting muscle protein synthesis [32].
Our study also showed that the BNP level was associ-
ated with increased muscle proteolysis, suggesting a
higher inflammatory status associated with severe HF
may have led to excessive muscle proteolysis.
In this study, the random forest algorithm revealed
that the BNP, LVEF, and inflammatory cytokines, in
addition to the skeletal muscle-related parameters,
played an important role in predicting the prognosis.
These parameters had relatively greater effects on the
prediction than the age, renal function, or hemoglobin
levels, which have been hitherto considered important in
predicting the prognosis. There have been many reports
in which elevated levels of IL-6 or CRP have been ob-
served in patients with HF and have a prognostic impli-
cation [33–35].
We showed that the random forest approach outper-
formed the logistic regression analysis and can be effect-
ively applied to predictive modeling in HF despite the
small number of observations and heterogeneous input
parameters. Originally, the random forest approach was
developed to explore the predictors of certain target
phenomena by using a large amount of data and is now
likely to become an alternate to explore predictors for
the target phenomena in healthcare or the events in clin-
ical medicine. The advantages of the random forest over
the logistic regression are that it can deal with compli-
cated combinations of different features and avoid over-
fitting. In addition, the random forest approach can
provide a systematic and quantitative way to assess fea-
ture importance. The logistic regression, however, is dif-
ficult to deal with highly correlated covariates and assess
the effect of each covariate. A logistic regression model
is not able to be applied when there are more independ-
ent variables than observations. The random forest could
overcome such difficulties. Our results using the logistic
regression demonstrate that BNP, age, and systolic blood
pressure were independent predictors. The random
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forest, however, shed light on the importance of the in-
flammatory cytokines and skeletal muscle wasting, which
were undetected in the logistic regression. Although the
importance of the skeletal muscle mass and strength in
HF patients was suggested in our analysis, further re-
search with other techniques is needed to understand
the hierarchy in selected predictors and the link among
the predictors.
We demonstrated that elderly HF patients, when
compared with age- and sex-matched controls, had
excessive skeletal muscle proteolysis and wasting and
the possibility that inflammation is an important
mechanism. The study showed that machine learning
analytics using data from inflammation and skeletal
muscle wasting can accurately predict outcomes. Op-
timizing the skeletal muscle mass and function in eld-
erly HF patients has become an important issue to
confer the quality of life and reduce the risk of death.
Although effective treatments except exercise training
currently remain to be established, future study is re-
quired to test whether pharmacological treatments
that modulate the inflammatory signaling pathways
that affect the muscle proteolysis and prognosis in
elderly HF patients.
Study limitations
This study was based on observations of a single-
center, small cohort of patients in a university hos-
pital. The small number of endpoints was a signifi-
cant limitation of the prognostic study. Physical
activity in daily life may vary between individuals and
may consequently have confounded the inflammatory
markers, skeletal muscle wasting, and functional cap-
acity. The TNF-α is one of the major inflammatory
cytokines in HF patients, but we did not measure the
TNF-α level. For the inclusion criteria of the control
subjects, we did not use the LVEF, but instead used a
BNP < 100 pg/mL and no history of hospitalization
due to worsening HF. This is because some of the
elderly patients might have subclinical HF irrespective
of LVEF at rest. Then, we considered that control
elderly subjects should have no overt sign of HF or
history of HF hospitalization at enrollment. However,
those with an LVEF< 50% in the controls may develop
HFrEF during long-term follow-up. We did not meas-
ure the fiber cross sectional area. The skeletal mass
estimation using CT / MRI was more useful than
ultrasonography, and ultrasonography may have lim-
ited their interpretation. The study patients were fully
compliant with the dietary instructions, but some nu-
tritional supplements may have affected the 3-MH. A
recent study, however, suggested that meat intake
does not affect the 3-MH [36].
Conclusion
This study provided evidence of the association between
inflammation and increased skeletal muscle proteolysis,
reduced skeletal mass and strength, and their prognostic
roles in elderly HF patients.
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